Ultragenyx Pharmaceutical Inc DTX301 Phase 1/2 Study in Ornithine Transcarbamylase (OTC) Deficiency Cohort 2 and 3 Data Update Transcript
Ladies and gentlemen, thank you for standing by, and welcome to the Ultragenyx' DTX301 Data Conference Call. (Operator Instructions) I would now like to hand the conference to your speaker today, Danielle Keatley, Senior Director of Investor Relations. Please go ahead, ma'am.
Thank you. Good afternoon, and welcome to the Ultragenyx conference call to discuss the results of the Phase I/II study of DTX301, our gene therapy for the treatment of OTC. We issued a press release earlier this afternoon detailing the data results. Slides to accompany this call are available through the webcast and can also be found on our website at ultragenyx.com.
With me today are Emil Kakkis, Chief Executive Officer and President of Ultragenyx; and Shalini Sharp, Chief Financial Officer.
I'd like to remind investors that this call will include forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
